End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15,200 KRW | +3.47% | +1.74% | -2.94% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- With a P/E ratio at 10.61 for the current year and 8.6 for next year, earnings multiples are highly attractive compared with competitors.
- The company shows low valuation levels, with an enterprise value at 533.57 times its sales.
- The company has a low valuation given the cash flows generated by its activity.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.94% | 236M | - | ||
+31.37% | 588B | B | ||
-2.79% | 364B | C+ | ||
+20.55% | 326B | B- | ||
+5.55% | 285B | C+ | ||
+14.83% | 239B | B+ | ||
+9.93% | 210B | B- | ||
-6.95% | 200B | A+ | ||
+11.02% | 167B | C+ | ||
+0.26% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A003220 Stock
- Ratings Daewon Pharmaceutical Co., Ltd.